TY - JOUR T1 - REVERSIBLE PRE-CAPILLARY PULMONARY HYPERTENSION DUE TO DASATINIB JF - Respiratory Care DO - 10.4187/respcare.02692 SP - respcare.02692 AU - Herminia L. Buchelli Ramirez AU - Celso M. Alvarez Alvarez AU - José J. Rodríguez Reguero AU - Marta M. García Clemente AU - Pere Casan Clará Y1 - 2013/10/22 UR - http://rc.rcjournal.com/content/early/2013/10/22/respcare.02692.abstract N2 - Pulmonary arterial hypertension (PAH) and secondary pleural effusion have been reported in association with long-term therapy with the multi tyrosine kinase inhibitor dasatinib, approved for the treatment of chronic myeloid leukemia (CML). We present the case of a 50-year-old man diagnosed with CML in August 2003, who developed PAH after more than four years of treatment with dasatinib. The complete remission of PAH following dasatinib discontinuation suggests an etiological role of the drug in its development, although the administration of sildenafil may have played a therapeutic role. ER -